50

Listed companies

23

Private companies

292

Insiders

Relation chart of related listed companies: Sanofi

Active Relations

Past Relations

Related listed companies: Sanofi

Active Relations

Past Relations

Relationship chart for related private companies: Sanofi

Active Relations

Past Relations

Related private companies: Sanofi

Bioverativ Therapeutics, Inc.

Pharmaceuticals: Major

Biotechnology Innovation Organization

Miscellaneous Commercial Services

The Royal Society

Investment Trusts/Mutual Funds

L'Oréal USA, Inc.

Medical Distributors

Sanofi-Aventis Deutschland GmbH

Pharmaceuticals: Major

National Academy of Sciences

Miscellaneous Commercial Services

Pharmaceutical Research & Manufacturers of America

Biotechnology

American Academy of Arts & Sciences

Miscellaneous Commercial Services

National Academy of Engineering

Miscellaneous Commercial Services

National Academy of Medicine (United States)

Miscellaneous Commercial Services

European Federation of Pharmaceutical Industries & Assns

Miscellaneous Commercial Services

Omnium Insurance & Reinsurance Co. Ltd.

Multi-Line Insurance

French Academy of Sciences

Other Consumer Services

L'Agence Nationale de la Recherche

General Government

Aventis Foundation

Stanford University School of Medicine

Dewpoint Therapeutics, Inc.

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Pharmaceuticals: Major10
Miscellaneous Commercial Services6
Biotechnology4
Medical Specialties2
Multi-Line Insurance2
Food: Meat/Fish/Dairy1
Personnel Services1
Information Technology Services1
Major Banks1
Wireless Telecommunications1

Countries of related companies

United States30
France23
Germany4
United Kingdom4
China3
Switzerland3
Belgium2
Bermuda1
Sweden1
Australia1
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).
Employees
82,878
More about the company